Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M)
Form 10-K Note 15/16 Taxes on Income
Latest, FY2025
2,500
Period ended Dec 31, 2025
Change on a year earlier
+10.6%
2,261 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,500 | +10.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 2,261 | -5.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 2,384 | +29.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1,835 | +20.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 1,529 | -0.5% | Form 10-K (filed 2025-02-25) ↗ |
| FY2020 | Dec 31, 2020 | 1,537 | +25.5% | Form 10-K (filed 2024-02-26) ↗ |
| FY2019 | Dec 31, 2019 | 1,225 | -35.3% | Form 10-K (filed 2023-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 1,893 | +9.9% | Form 10-K (filed 2022-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 1,723 | -50.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2016 | Dec 31, 2016 | 3,494 | – | Form 10-K (filed 2020-02-26) ↗ |
Breakdown
What makes up unrecognized tax benefits (utb) — ending balance ($m)
- UTB Rollforward — Gross Increases for Current-Year Tax Positions ($M)396 · FY2025
- UTB Rollforward — Gross Increases for Prior-Year Tax Positions ($M)59 · FY2025
- UTB Rollforward — Gross Decreases for Prior-Year Tax Positions ($M)94 · FY2025
- UTB Rollforward — Settlements with Taxing Authorities ($M)28 · FY2025
- Accrued Interest and Penalties on Unrecognized Tax Benefits ($M)546 · FY2025
- Income Tax Interest and Penalties Expense (Benefit) ($M)106 · FY2025
- Deferred Tax Assets — Gross ($M)7,557 · FY2025
- Deferred Tax Assets — Valuation Allowance ($M)824 · FY2025
- Deferred Tax Assets — Net ($M)6,733 · FY2025
- Deferred Tax Assets — Capitalized R&D and Acquired IPR&D ($M)4,134 · FY2025
- Deferred Tax Liabilities — Gross ($M)5,567 · FY2025
- Deferred Tax Liabilities — Intangible Assets ($M)3,272 · FY2025
- Net Deferred Tax Assets (Liabilities) ($M)1,166 · FY2025
- Effective Tax Rate Benefit from R&D Tax Credits (percentage points)1.2% · FY2025
Cite this data
StockData. (2026). Merck Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/tax_utb_bal
See every metric in the Merck KPI table. Data updated Oct 26, 2026.